GSK plc (LSE:GSK) is a British multinational pharmaceutical and biotechnology company founded in 1715, making it one of the world's oldest pharmaceutical companies. The company was formed through a series of mergers, most notably the 2000 merger of Glaxo Wellcome and SmithKline Beecham, and changed its name from GlaxoSmithKline plc to GSK plc in May 2022. Headquartered in Brentford, United Kingdom, GSK has evolved from a traditional pharmaceutical company into a focused biopharmaceutical enterprise specializing in vaccines and specialty medicines. The company operates globally with significant presence in the United States, Europe, and emerging markets, dedicating its efforts to preventing and treating diseases through innovative research and development.
$49.89
−1.93%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
9.8x
EV/EBITDA
8.1x
Market Cap
$99.96B
MomentumView details →
1D Return
−1.93%
YTD Return
+1.84%
RSI (14)
42.9
ValuationView details →
P/E (Fwd)
9.8x
EV/EBITDA
8.1x
Market Cap
$99.96B
RSI (14)
42.9
MomentumView details →
1D Return
−1.93%
YTD Return
+1.84%
SummaryUpdated Jun 1, 2026
Latest newsMore news →
Hutchison China MediTech and GlaxoSmithKline reached a licensing agreement for a KRAS-EGFR antibody-drug conjugate cancer drug.4d agoGlaxoSmithKline announced positive Phase 2 trial data and will advance development of a candidate vaccine.6d agoGSK and Relation Therapeutics entered into a research collaboration worth up to $110 million to generate human cellular datasets and train AI models for identifying potential new drug targets.39d ago